Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

N/ACompletedNCT01619007

Bayer5,145 enrolled

Overview

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT). The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute DVT in routine clinical practice.

Study Type

OBSERVATIONAL

Enrollment

5,145

Conditions

Deep Vein Thrombosis Venous Thrombosis

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban

Standard of careDRUG

Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female and male patients * Patients \>= 18 years * Patiebts with diagnosis of acute DVT and who have an indication for anticoagulation therapy for at least 12 weeks, who are willing to participate in this study and are available for follow-up Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information.

Locations (21)

Unnamed facility

Many Locations, Austria

Unnamed facility

Many Locations, Belgium

Unnamed facility

Many Locations, Canada

Outcomes

Primary Outcomes

Major bleedings defined as overt bleeding associated with: A fall in hemoglobin of ≥2 g/dL; or a transfusion of ≥2 units of packed red blood cells or whole blood; or occurrence at a critical site